跳至主要内容
临床试验/EUCTR2009-017622-39-SI
EUCTR2009-017622-39-SI进行中(未招募)不适用

A double blind, randomized study to compare influence of niacin/laropiprant on functional and morphological characteristics of arterial wall and parameters of inflammation in subjects with CHD already treated with a statin

Clinical Center Ljubljana0 个研究点目标入组 62 人开始时间: 2010年4月9日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
62

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
Male

入选标准

  • -age 35-55, with
  • -confirmed CHD (post MI patients, coronarography and/or cycloergometry)
  • -already treated for dyslipidemia with a statin and reaching ESC LDL target
  • -HDL-C <1.1 mmol/l, TG > 1,7 mmol/l and LDL < 2,6 mmol/L
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • -3x increase of liver enzyme tests or CK
  • -severe renal insufficiency – creatinin >200 mmol/l,
  • -acute disease within 6 weeks prior to inclusion,
  • -hypersensitivity to nicotinic acid
  • -other cardiac medication stable for at least 4 weeks prior to enrollment
  • -Acute MI, CABG, PCI within past 3 months.
  • -Congestive heart failure (CHF) _ NYHA 2.
  • -Ejection fraction < 40% measured within the past 6 months.
  • -Malignancy.
  • -HIV infection or immunodeficiency state.
  • -Stable dose of statin < 6 weeks
  • -Diabetes mellitus type 1.
  • -Diabetes mellitus type 2 with HbA1C > 7%
  • -Hypo/hyper thyroidism.
  • -Alcohol or drug abuse

研究者

发起方
Clinical Center Ljubljana

相似试验

A double blind, randomized study to compare... | 临床试验